Dementia presents an escalating public health challenge worldwide. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
for interaction <0.05). We identified a worse cognitive function and an increased mortality risk in dementia patients with RA compared with non-RA. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Living with another adult and higher MMSE scores were significantly associated with later access to home help services (p < 0.001) and care facilities (p < 0.001). 3 key findings →
Design: cohort study Participants: 2,592 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the Research Article "Magnitude and Time-Course of Dementia Risk in Stroke Survivors: A Population-Wide Matched Cohort Study" by Joundi et al., 1 the keys for Figure 3, A-D should indicate red for "Stroke," "Ischemic Stroke," "ICH," and "Stroke," respectively. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Increased UPF consumption is associated with higher risks of dementia, CIND, and CIND or dementia among US older adults. 4 key findings →
Design: cohort Participants: 5,370 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These data confirm that NPS are risk factors for conversion from CIND to dementia. 1 key finding →
Participants: 230 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
No associations between n-3 PUFAs and dementia or AD were found. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is a strong association between late-life depression, cognitive impairment, cerebrovascular disease, and poor cognitive outcomes, including progressive dementia, especially Alzheimer's disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caffeine has well-known short-term stimulating effects on central nervous system, but the long-term impacts on cognition have been less clear. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Elderly people taking anticholinergic drugs were at increased risk for cognitive decline and dementia. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
53/100
In recent years a rapidly increasing number of studies has focused on the relationship between dementia and metabolic disorders such as diabetes, obesity, hypertension, and dyslipidemia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinical studies found that elevated cortisol was associated with poorer overall cognitive functioning, as well as with poorer episodic memory, executive functioning, language, spatial memory, processing speed, and social cognition; while in animals, glucocorticoid administration resulted in cognitive impairment and abnormal behavior. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hypertension is a highly prevalent condition which has been established as a risk factor for cardiovascular and cerebrovascular disease. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment is an increasingly recognized comorbidity of diabetes, yet the mechanisms underlying this association remain poorly understood. 4 key findings →
Design: longitudinal study Participants: 654 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been linked to a decreased risk of dementia, but reverse causality and residual confounding by lifestyle may partly account for this link. 4 key findings →
Participants: 5,375 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty-three percent of LLD participants met ADNI criteria for mild cognitive impairment. 4 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
53/100
Fibroblast growth factor 23 is an emerging vascular biomarker, recently associated with cerebral small vessel disease and poor cognition in patients on dialysis. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
However, due to the synergistic effect between diabetic pathology and neuroinflammation, and the prothrombotic profile in patients with diabetes, whether vitamin D is associated with risk of dementia among patients with diabetes is unclear. 4 key findings →
Participants: 13,486 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Perceived greater access to greenspaces (estimate = 2.83, 95% CI = 1.40–4.26) and greater time in neighborhood greenspaces were associated with greater RI scores (estimate = 2.30, 95% CI = 1.24–3.35). 5 key findings →
Design: cross-sectional Participants: 162 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We examined factors associated with self-reported medication nonadherence in well-characterized community-based cohort of older adults. 5 key findings →
Design: cohort study Participants: 5,164 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Overall, 430 093 participants were included. 5 key findings →
Design: cohort study Participants: 93 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Significant interactions between amyloid status and modifiable risk factors were observed for diabetes (adjusted β = -0.206, p = 0.032), high cholesterol (adjusted β = -0.155, p < 0.001), and physical inactivity (adjusted β = -0.161, p = 0.046), indicating combined effects rather than additive effects on cognitive decline among Aβ+ individuals. 5 key findings →
Design: cohort study Participants: 1,707 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 400 103 AF and dementia-related deaths were recorded between 2000 and 2020. 5 key findings →
Participants: 400 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Midlife individuals who experienced HDP had lower regional CBF and reduced white matter microstructural integrity, compared with those with no adverse pregnancy outcomes. 5 key findings →
Design: prospective cohort Participants: 81 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over a mean follow-up of 14.6 years, 7.7% of the participants (n = 614) developed dementia. 5 key findings →
Participants: 7,960 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,040 records (3.4% of the library) are not peer-reviewed — 965 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events